These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 29172465)
1. A New Step in the Treatment of Sickle Cell Disease Ortiz de Montellano PR Biochemistry; 2018 Feb; 57(5):470-471. PubMed ID: 29172465 [No Abstract] [Full Text] [Related]
2. New and experimental agents for sickle cell disease. Ataga KI Clin Adv Hematol Oncol; 2018 Jul; 16(7):476-479. PubMed ID: 30067617 [No Abstract] [Full Text] [Related]
3. Cyclic Guanosine Monophosphate-Dependent Protein Kinase I Stimulators and Activators Are Therapeutic Alternatives for Sickle Cell Disease. Ghanta M; Panchanathan E; Lakkakula BV Turk J Haematol; 2018 Mar; 35(1):77-78. PubMed ID: 29192603 [No Abstract] [Full Text] [Related]
4. Hydroxyurea and new agents for the treatment of sickle cell disease. Rodgers GP Clin Adv Hematol Oncol; 2004 Nov; 2(11):713-5. PubMed ID: 16163257 [No Abstract] [Full Text] [Related]
5. Different ways to transport ammonia in human and Mycobacterium tuberculosis NAD Chuenchor W; Doukov TI; Chang KT; Resto M; Yun CS; Gerratana B Nat Commun; 2020 Jan; 11(1):16. PubMed ID: 31911602 [TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea for the treatment of sickle cell anemia. Platt OS N Engl J Med; 2008 Mar; 358(13):1362-9. PubMed ID: 18367739 [No Abstract] [Full Text] [Related]
7. Recent insights on the medicinal chemistry of sickle cell disease. Dos Santos JL; Chin CM Curr Med Chem; 2011; 18(15):2339-58. PubMed ID: 21517749 [TBL] [Abstract][Full Text] [Related]
8. Sickle-cell anemia: molecular and cellular bases of therapeutic approaches (third of three parts). Dean J; Schechter AN N Engl J Med; 1978 Oct; 299(16):863-70. PubMed ID: 692579 [No Abstract] [Full Text] [Related]
9. A view of the current status of antisickling therapy. Brewer GJ Am J Hematol; 1976; 1(1):121-8. PubMed ID: 790948 [No Abstract] [Full Text] [Related]
10. Two drugs for sickle cell disease. Med Lett Drugs Ther; 2020 Apr; 62(1595):51-52. PubMed ID: 32324178 [No Abstract] [Full Text] [Related]
11. The molecular basis of antisickling agents. Franklin IM; Huehns ER Trans R Soc Trop Med Hyg; 1980; 74(6):695-700. PubMed ID: 7210123 [No Abstract] [Full Text] [Related]
12. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors. Okam MM; Ebert BL Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210 [TBL] [Abstract][Full Text] [Related]
13. Understanding antisickling agents and the sickling process. Godwin M; Baysinger M Nurs Clin North Am; 1983 Mar; 18(1):207-14. PubMed ID: 6550864 [No Abstract] [Full Text] [Related]
14. Hydroxyurea treatment does not increase blood viscosity and improves red blood cell rheology in sickle cell anemia. Lemonne N; Charlot K; Waltz X; Ballas SK; Lamarre Y; Lee K; Hierso R; Connes C; Etienne-Julan M; Romana M; Connes P Haematologica; 2015 Oct; 100(10):e383-6. PubMed ID: 26137960 [No Abstract] [Full Text] [Related]
15. Hydroxyurea for sickle cell anemia. Naina HV; Harris S N Engl J Med; 2008 Jul; 359(1):98; author reply 98-9. PubMed ID: 18596283 [No Abstract] [Full Text] [Related]
16. Treatment adherence in patients with sickle cell anemia. Drotar D J Pediatr; 2010 Mar; 156(3):350-1. PubMed ID: 20056235 [No Abstract] [Full Text] [Related]
17. Future directions in sickle cell disease. Anand A West J Med; 1993 May; 158(5):536-7. PubMed ID: 8342283 [No Abstract] [Full Text] [Related]
18. Long-term use of hydroxyurea for sickle cell anemia. Lee DA; Mueller BU JAMA; 2003 Aug; 290(6):753-4; author reply 754. PubMed ID: 12915425 [No Abstract] [Full Text] [Related]